Stifel raised the firm’s price target on Janux Therapeutics (JANX) to $46 from $45 and keeps a Buy rating on the shares after a Q3 report the the firm says offered “no surprises” or incremental details. The firm continues to like the risk/reward into the year-end presentation of incremental JANX007 and JANX008 data updates, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics price target raised to $48 from $47 at Barclays
- Buy Rating for Janux Therapeutics: Promising Data and Strong Financial Position Highlight Growth Potential
- Janux Therapeutics Reports Strong Financial Position Amid Clinical Advancements
- Buy Rating on Janux Therapeutics Inc: Strong Financials and Promising Clinical Developments
- Promising Pipeline and Strategic Developments Justify Buy Rating for Janux Therapeutics Inc.